Anxiety Disorders and Depression Treatments Market With Top Players Like Pfizer Inc., GlaxoSmithKline Plc., H. Lundbeck A/S, Eli Lily and Company

Overview:

The anxiety and depression affect a huge number of population all over the world as they are the most common type of mental illness. Anxiety occurs in various forms depending on stress reaction of a person and it differs from people to people. Depression is the most known form of mental illness that globally affects large number of people. People suffering from anxiety face worry and fear severe than normal worrying, where the anxious phase of an individual worsens over time. Anxiety can have negative impact on job performance, relationships and school work. The anxiety disorder is categorized into three types, generalized anxiety, social anxiety, and panic disorders. Whereas, depression is associated with severe mood swings. It affects actions, thoughts and sleep pattern of a person. The severity of anxiety and depression cause phobias, panic disorder, post-traumatic disorders (PTSD) and obsessive compulsive disorder (OCD).

Get PDF Brochure Of This Report With Detailed Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/837

Drivers:

Rise in the number of mental illness cases such as anxiety and depression are increasing demand of anti-depressant drugs, which in turn is expected to propel growth of the global anxiety disorders and depression treatments market. For instance, in 2017, the World Health Organization (WHO) estimated around 300 million individuals around the world suffer from depression, and it has caused 800,000 deaths from suicide, which were mostly induced by depression and anxiety disorders.

Furthermore, as per the Anxiety and Depression Association of America, 18% of the U.S. population is affected by anxiety disorders, which the most common mental illness in the U.S. Moreover, According to the association, mental illness can be cured, which in turn is expected to fuel growth of the global anxiety disorders and depression treatment market.

Restraints:

Side effects caused by anti-depressants, and availability of alternate treatment options for psychological illness are expected to hinder growth of the global anxiety disorder and depression treatment market.

Regional analysis:

The global anxiety and depression treatment market is regionally divided into North America, Europe, Latin America, Middle East, Asia Pacific, and Africa.

Among regions, North America is expected to witness a strong growth in the anxiety disorder and depression treatment market due to increasing prevalence of mental disorders associated with stress, anxiety, and depression. For instance, in 2014, the Mental Health America reported 1 out of 5 adults suffer from mental illness and as observed, the illness in younger population is rapidly worsening.

Moreover, Asia Pacific is witnessing robust growth in the global anxiety disorder and depression treatment market, owing to changing life style and growing stress of work in middle-income countries like China and India.

Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/837

Market taxonomy:

The global anxiety and depression treatment market is divided into drug, distribution channel and geography.

By drug class:

• SRIs (Selective Serotonin Reuptake Inhibitors)

• SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

• TeCAs (Tetracyclic Antidepressants)

• TCAs (Tricyclic Antidepressants)

• MAOIs (Monoamine Oxidase inhibitors)

• Atypical Antipsychotics

• Benzodiazepines

• Anticonvulsants 

• Beta-Blockers

• Others

By distribution channel:

• Pharmacies

• E-Commerce

Key takeaways:

The anti-depressant medications dominate the global pharmaceutical market with 50% of the market share. Technological development in the treatment of mental illness such as medical implants used for brain stimulation and virtual reality exposure treatments conducted on smartphone based apps are supporting growth of the global market of anxiety disorder and depression treatment.

Key players:

Major players active in the global anxiety disorders and depression treatments market include GlaxoSmithKline Plc., Eli Lily and Company, Inc., AstraZeneca Plc, Sanofi Aventis Johnson and Johnson, Pfizer Inc., H. Lundbeck A/S, Merck and Company, Inc., and Forest Laboratories.